![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.
Preview |
PDF
- Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
137kB |
Abstract
For the 32 prioritisation (August 2017), 10 drugs were filtered out of 366 identified and were sent to
prioritisation. Of these, 5 drugs were ranked as "highly relevant" by the expert panel, 5 as "relevant" and none as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.
| Item Type: | DSD: Horizon Scanning in Oncology |
|---|---|
| Subjects: | WB Practice of medicine > WB 300-962 Therapeutics QZ Pathology > QZ 200-380 Neoplasms.Cysts QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology |
| Language: | English |
| Series Name: | HSO: 32nd Prioritisation |
| Deposited on: | 23 Aug 2017 10:46 |
| Last Modified: | 15 Jul 2020 17:56 |
Repository Staff Only: item control page